title: Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA.
abstract: Contacts of persons infected with multidrug-resistant tuberculosis (MDR TB) have few prophylaxis options. Of 50 contacts of HIV- and MDR TB-positive persons who were treated with moxifloxacin, 30 completed treatment and 3 discontinued treatment because of gastrointestinal symptoms. Moxifloxacin was generally well-tolerated; further research of its efficacy against MDR TB is needed.
authors.forename: Lisa
authors.initials: L
authors.lastname: Trieu
authors.forename: Douglas C
authors.initials: DC
authors.lastname: Proops
authors.forename: Shama D
authors.initials: SD
authors.lastname: Ahuja
mesh_terms: D019072:Antibiotic Prophylaxis; D000995:Antitubercular Agents / Q000627:therapeutic use*; D060085:Coinfection; D024841:Fluoroquinolones / Q000627:therapeutic use*; D005500:Follow-Up Studies; D015658:HIV Infections; D006801:Humans; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis; D009519:New York City / Q000453:epidemiology; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D000995:Antitubercular Agents; D024841:Fluoroquinolones; D000077266:Moxifloxacin